Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 plus standard immunosuppressive therapy in adult aplastic anemia (observational, single-arm)
ChiCTR2600120617Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in aplastic anemia, sponsored by Henan Cancer Hospital. Primary endpoint: Complete Hematologic Response Rate at Week 14. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2600120617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120617.